Cost-effectiveness of testing for human immunodeficiency virus and hepatitis C virus among blood transfusion recipients

被引:2
|
作者
Mathoulin-Pelissier, S [1 ]
Salmi, LR [1 ]
Fialon, P [1 ]
Salamon, R [1 ]
机构
[1] Bordeaux Univ Hosp, Bordeaux, France
来源
INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY | 2003年 / 24卷 / 02期
关键词
D O I
10.1086/502170
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
OBJECTIVE: To choose the most cost-effective option for detecting human immunodeficiency virus (HIV-1) and hepatitis C virus (HCV) among blood transfusion recipients. DESIGN: Cost-effectiveness analysis. Effectiveness was expressed as the number of HIV-1 or HCV infections detected, regardless of whether they were related to transfusion. To estimate costs, we assumed hospital insurance would cover costs related to detection and compensation, when granted. SETTING: A 2,890-bed acute care teaching hospital in Bordeaux, France. METHODS: Eight options were defined, from the simplest, which would be to do nothing, to a maximal approach, which would be to keep a serum sample in a serum library for a lookback and perform tests for antibody to HIV-1 and to HCV before and 3 months after transfusion. Data on probabilities and costs were taken from the literature and experiences of French hospitals. RESULTS: The most cost-effective option was to perform viral antibody testing before transfusions (option 3), which would detect 27 infections per 1,000 patients, for an expenditure of US $1,260 per detected patient. Option 6, obtaining a serum sample before transfusion and performing tests for antibody to HIV-1 and to HCV 3 months after transfusion, had a similar cost-effectiveness ratio but detected only 16 infections per 1,000 patients. Performing tests before and 3 months after transfusion (option 4), compared with option 3, would detect 1 additional infection for an additional cost of US $8,322. CONCLUSION: The most cost-effective options are not specific to blood transfusion recipients and might be more suited to all hospitalized patients.
引用
收藏
页码:132 / 136
页数:5
相关论文
共 50 条
  • [1] The cost-effectiveness of introducing nucleic acid testing to test for hepatitis B, hepatitis C, and human immunodeficiency virus among blood donors in Sweden
    Davidson, Thomas
    Ekermo, Bengt
    Gaines, Hans
    Lesko, Birgitta
    Akerlind, Britt
    TRANSFUSION, 2011, 51 (02) : 421 - 429
  • [2] Cost-effectiveness (CE) of screening donated blood with minipool nucleic acid testing (NAT) for hepatitis B virus (HBV), hepatitis C virus (HCV), and human immunodeficiency virus (HIV)
    Grima, DT
    Marshall, D
    Weinstein, M
    Wong, JB
    Kleinman, S
    AuBuchon, J
    VALUE IN HEALTH, 2002, 5 (06) : 446 - 446
  • [3] Cost-effectiveness of expanded human immunodeficiency virus-testing protocols for donated blood
    AuBuchon, JP
    Birkmeyer, JD
    Busch, MP
    TRANSFUSION, 1997, 37 (01) : 45 - 51
  • [4] Treatment for hepatitis C virus in human immunodeficiency virus-infected patients - Clinical benefits and cost-effectiveness
    Kuehne, FC
    Bethe, U
    Freedberg, K
    Goldie, SJ
    ARCHIVES OF INTERNAL MEDICINE, 2002, 162 (22) : 2545 - 2556
  • [5] Cost-effectiveness of treatment for chronic hepatitis C infection in patients coinfected with human immunodeficiency virus
    Servoss, JC
    Campos, NG
    Salomon, JA
    Freedberg, KA
    Samet, JH
    Goldie, SJ
    Chung, RT
    HEPATOLOGY, 2005, 42 (04) : 350A - 350A
  • [6] Cost-effectiveness of strategies for testing current hepatitis C virus infection
    Chapko, Michael K.
    Dufour, D. Robert
    Hatia, Rikita I.
    Drobeniuc, Jan
    Ward, John W.
    Teo, Chong-Gee
    HEPATOLOGY, 2015, 62 (05) : 1396 - 1404
  • [7] Effectiveness of post-transfusion controls for human immunodeficiency virus, hepatitis B and C viruses, and alanine-aminotransferase in blood recipients
    Renaudier, P
    Vial, J
    Augey, L
    Garin, L
    Durand, B
    Chevallier, P
    Ritter, J
    Tardy, J
    Deldon, M
    Grafmeyer, D
    Du Gres, BD
    TRANSFUSION, 2003, 43 (09) : 115A - 116A
  • [8] A new strategy to improve the cost-effectiveness of human immunodeficiency virus, hepatitis B virus, hepatitis C virus, and syphilis testing of blood donations in sub-Saharan Africa: a pilot study in Burkina Faso
    Kania, Dramane
    Sangare, Lassana
    Sakande, Jean
    Koanda, Abdoulaye
    Nebie, Yacouba Kompingnin
    Zerbo, Oumarou
    Combassere, AlainWilfried
    Guissou, Innocent Pierre
    Rouet, Francois
    TRANSFUSION, 2009, 49 (10) : 2237 - 2240
  • [9] Cost effectiveness of adding nucleic acid testing to hepatitis B, hepatitis C, and human immunodeficiency virus screening of blood donations in Zimbabwe
    Mafirakureva, Nyashadzaishe
    Mapako, Tonderai
    Khoza, Star
    Emmanuel, Jean C.
    Marowa, Lucy
    Mvere, David
    Postma, Maarten J.
    van Hulst, Marinus
    TRANSFUSION, 2016, 56 (12) : 3101 - 3111